Skip to content
AnalystLens

IDEXX Laboratories 8-K Report, Financial Results (Nov 2, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed November 2, 2026
Period End
November 2, 2026
Security
IDXX
In the record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Oct ’19Oct ’19
  2. Material agreement8-K · Dec ’21Dec ’21
  3. Leadership change8-K · Jan ’26Jan ’26

Summary

Summary of the 8-K filed November 2, 2026. Cited figures are marked; the original filing is the authoritative source.

IDEXX Laboratories, Inc. (IDXX) announced robust financial results for the third quarter ended September 30, 2026.

The company reported a 10% increase in revenue on both a reported and organic basis, reaching $1,214 milliona. This growth was primarily driven by the Companion Animal Group (CAG) segment, which saw an 11% increase in recurring revenue, signaling strong performance in its core diagnostics and consumables offerings. Earnings per diluted share (EPS) also showed significant improvement, rising 18% year-over-year to $4.01.

The company demonstrated its confidence in continued success by raising its full-year 2026 guidance for both revenue and EPS. Revenue guidance was increased to a range of $4,741 million to $4,767 millionb, with the midpoint reflecting a $32 million increase.

The EPS outlook was also raised to $14.96c - $15.16. This positive outlook is supported by strong operational execution, benefits from IDEXX's innovations, and strategic acquisitions like CoVet, which is expected to enhance veterinary team productivity.

Key Highlights

  1. Third quarter revenue grew 10% year-over-year, reaching $1,214 million.
  2. Companion Animal Group (CAG) Diagnostics recurring revenue increased by 11%, showcasing strength in core offerings.
  3. Earnings Per Share (EPS) rose 18% to $4.01, demonstrating significant profit growth.
  4. The company raised its full-year 2026 revenue guidance to $4,741 million - $4,767 million.
  5. Full-year 2026 EPS outlook was increased to $14.96 - $15.16.
  6. Installation of over 1,900 IDEXX inVue Dx™ analyzers contributed to an installed base of nearly 11,000 instruments.
  7. Acquisition of CoVet, an AI clinical assistant, was highlighted as a strategic move to enhance veterinary productivity.

Frequently Asked Questions

  1. What were the key drivers of IDEXX's revenue growth in Q3 2026?

    Revenue growth was primarily driven by strong volume expansion in the Companion Animal Group (CAG) Diagnostics segment, benefiting from IDEXX's innovations, excellent commercial execution, and an expanding installed base of analyzers. Specifically, CAG Diagnostics recurring revenue saw an 11% increase.

  2. How is IDEXX updating its financial outlook for the full year 2026?

    IDEXX has raised its full-year 2026 guidance for both revenue and EPS. The revenue outlook is now between $4,741 million and $4,767 million, with an increased midpoint. The EPS outlook has also been raised to a range of $14.96 to $15.16.

  3. What is the significance of the IDEXX inVue Dx™ analyzer placements?

    The company placed over 1,900 IDEXX inVue Dx™ analyzers during the quarter, growing the installed base to nearly 11,000 instruments. This expansion is crucial as it drives recurring revenue from consumables and services, a key component of IDEXX's business model.

  4. What impact did the CoVet acquisition have on the results and outlook?

    The acquisition of CoVet, an AI clinical assistant, was mentioned as a strategic addition to enhance veterinary team productivity and diagnostics utilization. While the acquisition has associated impacts, the company raised its guidance, indicating confidence in its ability to integrate and leverage this acquisition for future growth.